Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

NCT01772199 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: GSK239512
DRUG: Placebo

Sponsor

GlaxoSmithKline